CKAP2L, or Cytoskeleton-Associated Protein 2-like, is a protein that plays a critical role in cellular processes, especially in the context of mitosis and cell division. As part of the larger cytoskeletal network, CKAP2L is intricately linked with microtubules and aids in the stabilization of these structures. Microtubules are fundamental for various cellular processes including intracellular transportation and the segregation of chromosomes during cell division. Therefore, the stability and dynamics of these structures have direct implications on the proper functioning of the cell.
CKAP2L inhibitors are molecules designed to interfere with the normal functioning of the CKAP2L protein. By targeting CKAP2L, these inhibitors disrupt the protein's association with microtubules, potentially destabilizing these structures. Since microtubules play pivotal roles in cellular activities, their destabilization can lead to the interruption of many cellular processes, particularly mitosis. The biochemical activity and selectivity of CKAP2L inhibitors make them a subject of significant research interest. Studies focused on the mechanistic pathways and the cellular consequences of inhibiting CKAP2L provide valuable insights into cellular biology and the broader implications of microtubule dynamics. When investigating CKAP2L inhibitors, researchers typically use various biochemical assays, molecular dynamics simulations, and cellular studies to elucidate their precise mechanism of action and the resulting cellular effects.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Alvocidib is a synthetic flavonoid derivative known for its potent inhibitory effects on cyclin-dependent kinases (CDKs). It's commonly recognized as a pan-CDK inhibitor. In the context of CKAP2L, it was found that depleting CKAP2L increased the sensitivity of certain cancer cells (specifically non-small cell lung cancer cells) to Alvocidib. This led to a significant reduction in cell proliferation, implying that Alvocidib could potentially inhibit CKAP2L activity. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Although the specific mechanism of Ribociclib's interaction with CKAP2L is not fully elucidated, it is suggested that Ribociclib's inhibition of CDK4/6 might be related to CKAP2L's role in cancer progression, particularly in the process of cell cycle and mitosis. | ||||||